Literature DB >> 34178496

Pembrolizumab-Associated Seronegative Myasthenia Gravis in a Patient With Metastatic Renal Cell Carcinoma.

Shaunak K Pandya1, Matthew Ulrickson2, JiaXi Dong1, Ryan Willen1, Arati Pandya1.   

Abstract

Seronegative myasthenia gravis is a rare, but potential adverse effect of immune checkpoint inhibition. There have been few but increasing number of cases reported in recent years, and early recognition is important for prompt diagnosis and management. Here, we describe the case of a 65-year-old male with metastatic renal cell carcinoma on pembrolizumab diagnosed with new-onset seronegative myasthenia gravis and review literature on its management.
Copyright © 2021, Pandya et al.

Entities:  

Keywords:  autoimmune; checkpoint inhibitors; intravenous immunoglobulin (ivig); myasthenia gravis; pembrolizumab; renal cell carcinoma (rcc); seronegative

Year:  2021        PMID： 34178496      PMCID： PMC8216640          DOI： 10.7759/cureus.15174

Source DB:  PubMed          Journal:  Cureus        ISSN： 2168-8184


  14 in total

1.  Pembrolizumab-induced myasthenia gravis: A fatal case report.

Authors:  Katherine L March; Michael J Samarin; Amik Sodhi; Ryan E Owens
Journal:  J Oncol Pharm Pract       Date:  2017-02-01       Impact factor: 1.809

Review 2.  Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors.

Authors:  D Makarious; K Horwood; J I G Coward
Journal:  Eur J Cancer       Date:  2017-06-27       Impact factor: 9.162

3.  PD-L2 is a second ligand for PD-1 and inhibits T cell activation.

Authors:  Y Latchman; C R Wood; T Chernova; D Chaudhary; M Borde; I Chernova; Y Iwai; A J Long; J A Brown; R Nunes; E A Greenfield; K Bourque; V A Boussiotis; L L Carter; B M Carreno; N Malenkovich; H Nishimura; T Okazaki; T Honjo; A H Sharpe; G J Freeman
Journal:  Nat Immunol       Date:  2001-03       Impact factor: 25.606

4.  Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis.

Authors:  H B Wang; F D Shi; H Li; B J Chambers; H Link; H G Ljunggren
Journal:  J Immunol       Date:  2001-05-15       Impact factor: 5.422

Review 5.  PD-1 and its ligands in tolerance and immunity.

Authors:  Mary E Keir; Manish J Butte; Gordon J Freeman; Arlene H Sharpe
Journal:  Annu Rev Immunol       Date:  2008       Impact factor: 28.527

6.  Myasthenia gravis: a review.

Authors:  Annapurni Jayam Trouth; Alok Dabi; Noha Solieman; Mohankumar Kurukumbi; Janaki Kalyanam
Journal:  Autoimmune Dis       Date:  2012-10-31

Review 7.  Development of the Inhibitors that Target the PD-1/PD-L1 Interaction-A Brief Look at Progress on Small Molecules, Peptides and Macrocycles.

Authors:  Katarzyna Guzik; Marcin Tomala; Damian Muszak; Magdalena Konieczny; Aleksandra Hec; Urszula Błaszkiewicz; Marcin Pustuła; Roberto Butera; Alexander Dömling; Tad A Holak
Journal:  Molecules       Date:  2019-05-30       Impact factor: 4.411

8.  Toxicities associated with checkpoint inhibitors-an overview.

Authors:  Laura Spiers; Nicholas Coupe; Miranda Payne
Journal:  Rheumatology (Oxford)       Date:  2019-12-01       Impact factor: 7.580

Review 9.  Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society.

Authors:  Nico Melzer; Tobias Ruck; Peter Fuhr; Ralf Gold; Reinhard Hohlfeld; Alexander Marx; Arthur Melms; Björn Tackenberg; Berthold Schalke; Christiane Schneider-Gold; Fritz Zimprich; Sven G Meuth; Heinz Wiendl
Journal:  J Neurol       Date:  2016-02-17       Impact factor: 4.849
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.